Tweet
In response to a flurry of new interest in the Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data Challenge we have decided to extend the submission period to March 13th. New guidance is available on the challenge site including updated evaluation criteria and anomaly examples.
Please also note that providing code is no longer required for a valid final submission. Selected contributors will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. We are also pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the challenge and the insights that emerge from it.
If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!
If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.
Please also note that providing code is no longer required for a valid final submission. Selected contributors will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. We are also pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the challenge and the insights that emerge from it.
If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!
If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.